Surrogate markers and joint models for longitudinal and survival data
- 20 December 2002
- journal article
- Published by Elsevier in Controlled Clinical Trials
- Vol. 23 (6) , 626-634
- https://doi.org/10.1016/s0197-2456(02)00234-9
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- A Measure of the Proportion of Treatment Effect Explained by a Surrogate MarkerBiometrics, 2002
- Bayesian estimation of the proportion of treatment effect captured by a surrogate marker.Statistics in Medicine, 2002
- Considerations in the Evaluation of Surrogate Endpoints in Clinical TrialsControlled Clinical Trials, 2001
- Confidence intervals and statistical power of the ‘Validation’ ratio for surrogate or intermediate endpointsJournal of Statistical Planning and Inference, 2001
- An Evaluation of a Measure of the Proportion of the Treatment Effect Explained by a Surrogate MarkerControlled Clinical Trials, 1998
- Criteria for the Validation of Surrogate Endpoints in Randomized ExperimentsPublished by JSTOR ,1998
- ESTIMATING THE PROPORTION OF TREATMENT EFFECT EXPLAINED BY A SURROGATE MARKERStatistics in Medicine, 1997
- A unified approach for modeling longitudinal and failure time data, with application in medical monitoringPublished by Institute of Electrical and Electronics Engineers (IEEE) ,1996
- Statistical validation of intermediate endpoints for chronic diseasesStatistics in Medicine, 1992
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989